Kasvu Therapeutics has raised €30 million in a Series A financing round led by Hadean Ventures. The funding will advance its novel TrkB potentiator into clinical development targeting neuropsychiatric disorders.
Amount Raised
€30 Million
Round Type
Series A
HelsinkiBiotechnologyHealth CareTherapeuticsInvestors
Description
Kasvu Therapeutics, a company focused on developing neuroplastogens, announced its €30 million Series A financing round. The round was led by Hadean Ventures with participation from various investors including Tesi and Innovestor Life Science Fund. The funds will aid in advancing its lead candidate KTX-0141 through clinical development. Clinical trials are anticipated to start in the latter half of 2027.
Quick answer
Kasvu Therapeutics raised €30 Million in a Series A round, dated September 24, 2026. Investors: Tesi, Innovestor Life Science Fund, Finnish Drug Discovery Center, Stephen Industries, Nordic Science Investments, Helsinki University Funds and Hadean Ventures. Kasvu Therapeutics is based in Helsinki, Uusimaa, Finland.
- How much did Kasvu Therapeutics raise?
- Kasvu Therapeutics raised €30 Million in a Series A round on September 24, 2026.
- Who invested in Kasvu Therapeutics?
- Tesi, Innovestor Life Science Fund, Finnish Drug Discovery Center, Stephen Industries, Nordic Science Investments, Helsinki University Funds and Hadean Ventures are named as investors in this round.
- What does Kasvu Therapeutics do?
- Kasvu Therapeutics is developing a new generation of neuroplastogens for neuropsychiatric and neurodegenerative disorders.
- Where is Kasvu Therapeutics based and how big is it?
- Kasvu Therapeutics is based in Helsinki, Uusimaa, Finland. Fundz records about 2 employees.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Kasvu Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- BioVie raised $4.7M (Post-IPO Equity) on November 6, 2026.
- Alethio raised $90M (Series A) on November 5, 2026.
- MyoPax raised an undisclosed amount (Pre-Seed) on November 4, 2026.
- Emvena Therapeutics raised an undisclosed amount (Seed) on November 4, 2026.
- Biograil raised $22M on November 4, 2026.
- Thryv Therapeutics raised $30M (Series B) on November 3, 2026.
Who to call at Kasvu Therapeutics, and when
A new round usually means Kasvu Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Kasvu Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Kasvu Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Kasvu Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Kasvu Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansKasvu Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.